Treatment of Acute Respiratory Distress Syndrome (ARDS)
AssigneeMelior Pharmaceuticals I, Inc.
InventorsAndrew G. Reaume, Gennady Smagin
Life of this patent
Estimating the term…
Abstract
Methods of preventing, delaying, or reducing the severity of pulmonary extravasation, pulmonary edema, pneumonia, fluid in the lung, acute respiratory distress syndrome, plasma extravasation, and/or pulmonary conditions that develop as a result of hypercytokinemia (cytokine storm syndrome) in a mammal having a medical condition by administering a lyn kinase activator are provided herein.
Claims34
A method of preventing, delaying, or reducing the severity of pulmonary extravasation, pulmonary edema, pneumonia, fluid in the lung, acute respiratory distress syndrome, plasma extravasation, and/or pulmonary conditions that develop as a result of hypercytokinemia (cytokine storm syndrome) in a mammal having a medical condition, the method comprising administering to the mammal a compound having the formula:
- wherein:
- R1 is an alkyl group;
- X is a halogen;
- Y is O, S, or NH;
- Z is O or S;
- n is an integer from 0 to 5 and m is 0 or 1, wherein m+n is less than or equal to 5;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.